Review article · 2025 · Open access
Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects
Frontiers in Immunology, 16, 1658867 · Published 20 November 2025 · DOI 10.3389/fimmu.2025.1658867
In brief
“Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects” is a 2025 review article by Mingxuan Zheng and 2 co-authors, published in Frontiers in Immunology. OpenAlex counts 1 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.09
- References
- 149
- Authors
- 3
Abstract
Autoimmune diseases (AID) comprise a diverse group of disorders driven by aberrant B-cell and T-cell reactivity against self-tissues. In recent years, cell-based therapies utilizing engineered T cells have emerged as a promising therapeutic strategy for AIDs. Notably, chimeric antigen receptor (CAR)-T cells have demonstrated the ability to selectively target and eliminate autoreactive immune populations, including pathogenic B cells and antibody-producing plasma cells. Beyond T-cell modulation, macrophages (MΦs) exhibit remarkable plasticity, differentiating into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes in response to microenvironmental cues. Advances in genetic engineering have enabled the development of CAR-MΦs (CAR-M), which hold potential for adoptive immunotherapy in certain diseases. However, CAR-M therapy remains experimental and requires further clinical validation. This review systematically evaluates the therapeutic potential of CAR-T and CAR-M in AIDs, comparing their respective advantages and limitations to provide a comprehensive foundation for future translational applications.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zheng, M., Chen, J., & Yang, H. (2025). Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects. Frontiers in Immunology, 16, 1658867. https://doi.org/10.3389/fimmu.2025.1658867
MLA 9
Zheng, Mingxuan, et al. “Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects.” Frontiers in Immunology, vol. 16, 2025, p. 1658867. https://doi.org/10.3389/fimmu.2025.1658867.
Chicago
Zheng, Mingxuan, Jiale Chen, and Hong Yang. 2025. “Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects.” Frontiers in Immunology 16: 1658867. https://doi.org/10.3389/fimmu.2025.1658867.
Harvard
Zheng, M., Chen, J. and Yang, H. (2025) ‘Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects’, Frontiers in Immunology, 16, p. 1658867. doi:10.3389/fimmu.2025.1658867.
IEEE
M. Zheng, J. Chen, and H. Yang, “Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects,” Frontiers in Immunology, vol. 16, p. 1658867, 2025, doi: 10.3389/fimmu.2025.1658867.
BibTeX
@article{zheng2025engineered,
title = {{Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects}},
author = {Zheng, Mingxuan and Chen, Jiale and Yang, Hong},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
pages = {1658867},
doi = {10.3389/fimmu.2025.1658867},
url = {https://doi.org/10.3389/fimmu.2025.1658867}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- autoimmune disease
- chimeric antigen receptor T cells
- CAR macrophages
- engineered T cells
- adoptive immunotherapy
- autoreactive B cells
- plasma cells
- macrophage polarization
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zheng, M., Chen, J., & Yang, H. (2025). Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects. Frontiers in Immunology, 16, 1658867. https://doi.org/10.3389/fimmu.2025.1658867
How many times has this paper been cited?
1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Mingxuan Zheng, Jiale Chen, Hong Yang.
What is the DOI of this paper?
10.3389/fimmu.2025.1658867, permanently at https://doi.org/10.3389/fimmu.2025.1658867. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.